Cerevel Therapeutics (NASDAQ:CERE – Get Free Report) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.02, Briefing.com reports. During the same quarter last year, the firm posted ($0.61) earnings per share. Cerevel Therapeutics Price Performance CERE traded […]
Cerevel Therapeutics (NASDAQ:CERE – Get Free Report) issued its earnings results on Wednesday. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.02, Briefing.com reports. During the same quarter in the previous year, the firm earned ($0.61) earnings per share. Cerevel Therapeutics Trading Down 9.9 […]
Cerevel Therapeutics (NASDAQ:CERE – Get Free Report) will release its earnings data before the market opens on Wednesday, August 2nd. Analysts expect Cerevel Therapeutics to post earnings of ($0.67) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link. Cerevel Therapeutics (NASDAQ:CERE – Get […]
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Rating) has earned a consensus rating of “Moderate Buy” from the twelve brokerages that are covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price target among analysts that […]